Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo
| | |

Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo

On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced that data evaluating LAGEVRIO(molnupiravir), an investigational oral antiviral COVID-19…

Icosavax announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).

Icosavax announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).

On Mar. 25, 2022, Icosavax announced the first subjects had been dosed with IVX-411, a virus-like particle (VLP)…